Recombinant SARS-CoV-2 Nucleocapsid antibody

Catalog No. ABIN6953060

This Human Monoclonal antibody specifically detects SARS-CoV-2 Nucleocapsid in ELISA and IF. It exhibits reactivity toward SARS Coronavirus-2 (SARS-CoV-2) and SARS Coronavirus (SARS-CoV)and has been mentioned in 1 publication.

Quick Overview for Recombinant SARS-CoV-2 Nucleocapsid antibody (ABIN6953060)

Target: SARS-CoV-2 Nucleocapsid (SARS-CoV-2 N)

Antibody Type: Recombinant Antibody

Reactivity: SARS Coronavirus-2 (SARS-CoV-2), SARS Coronavirus (SARS-CoV)

Host: Human

Clonality: Monoclonal

Conjugate: This SARS-CoV-2 Nucleocapsid antibody is un-conjugated

Application: ELISA, Immunofluorescence (IF)

Clone: CR3009 (03-009)

Product Details anti-SARS-CoV-2 Nucleocapsid Antibody

Purpose: Anti-Covid-19 & SARS-CoV Nucleoprotein [CR3009 (03-009)], Human IgG1, kappa

Specificity: This antibody recognizes and binds the non-linear/conformational epitope of the N protein of SARS CoV and also binds the SARS CoV2 nucleoprotein.

Cross-Reactivity: SARS Coronavirus-2 (SARS-CoV-2)

Characteristics:

Original Species of Ab: Human

Original Format of Ab: IgG1

Purification: Protein A affinity purified

Immunogen: The original antibody was generated by cloning the variable regions of the scFvs selected from phage display libraries into separate vectors for IgG1 heavy-chain and light-chain expression. The harvested supernatents were then purified on protein A columns. The original antigen was the whole irradiated virion.

Isotype: IgG1 kappa

Application Details

Application Notes: This antibody is recommended for detection of SARS CoV2 protein N (nucleoprotein). This antibody binds both the nucleocapsid protein of the SARS-CoV and SARS CoV-2 (2019-nCoV). Initial characterization of the antibody for binding to 2019-nCoV was done using ELISA. This antibody shows potential to be used for development of diagnostic assays. Various isotype versions of the antibody namely human IgG1, IgG3, IgM, IgA and the less common IgG2 and IgG4 are available for the investigation of their role in response to SARS CoV2. Competitive ELISA of this antibody with CR3018 suggests that both these antibodies bind different epitopes of the N protein of SARS CoV. Thus, a combination of these two antibodies is suggested for virus capture assays. Immunofluorescence staining was used to demonstrate binding of CR3009 to SARS-CoV infected Vero cells. (PMID:15650189)

Restrictions: For Research Use only

Handling

Format: Liquid

Concentration: 1 mg/mL

Buffer: PBS with 0.02 % Proclin 300.

Preservative: ProClin

Precaution of Use: This product contains ProClin: a POISONOUS AND HAZARDOUS SUBSTANCE which should be handled by trained staff only.

Storage: 4 °C,-20 °C

Storage Comment: Store at 4°C for up to 3 months. For longer storage, aliquot and store at -20°C.

References for anti-SARS-CoV-2 Nucleocapsid antibody (ABIN6953060)

van den Brink, Ter Meulen, Cox, Jongeneelen, Thijsse, Throsby, Marissen, Rood, Bakker, Gelderblom, Martina, Osterhaus, Preiser, Doerr, de Kruif, Goudsmit: "Molecular and biological characterization of human monoclonal antibodies binding to the spike and nucleocapsid proteins of severe acute respiratory syndrome coronavirus." in: Journal of virology, Vol. 79, Issue 3, pp. 1635-44, (2005) (PubMed).

Target Details for SARS-CoV-2 Nucleocapsid

Target: SARS-CoV-2 Nucleocapsid (SARS-CoV-2 N)

Alternative Name: SARS-CoV-2 Nucleocapsid Protein

Target Type: Viral Protein

Background: NP, NC, Protein N, Nucleocapsid protein, SARS-CoV Protein N, SARS-CoV Nucleocapsid protein, SARS Coronavirus, SARS-CoV-2, SARS CoV 2, 2019-nCoV

UniProt: P0DTC9, P59595